Lyell Immunopharma (NASDAQ:LYEL) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings results on Thursday. The company reported ($1.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.02) by $0.10, reports. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 87.60%. The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.01 million.

Lyell Immunopharma Stock Performance

Shares of LYEL stock traded up $0.50 during mid-day trading on Friday, hitting $14.71. 110,955 shares of the stock traded hands, compared to its average volume of 170,417. Lyell Immunopharma has a twelve month low of $9.28 and a twelve month high of $45.00. The company’s 50-day simple moving average is $13.44 and its 200-day simple moving average is $19.01. The firm has a market cap of $360.39 million, a price-to-earnings ratio of -1.15 and a beta of -0.04.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LYEL. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Citizens Jmp reissued a “market outperform” rating and set a $34.00 price objective on shares of Lyell Immunopharma in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LYEL. Charles Schwab Investment Management Inc. lifted its stake in Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after buying an additional 5,913 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of Lyell Immunopharma during the 4th quarter worth approximately $262,000. Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at $94,000. Two Sigma Investments LP increased its stake in shares of Lyell Immunopharma by 107.0% in the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after acquiring an additional 10,768 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter valued at $382,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.